As the prophylactic use of TKI is being extensively used, preferably using the TKI administered prior transplantation, unless an ABL1 mutation occurs, the method of TKI administration after transplant has been addressed only in a small, randomized trial from the German multicenter study group for adult ALL (GMALL) [46]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.